EN DE
Watch CARsgen Therapeutics Holdings Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CARsgen Therapeutics Holdings Limited (CRTHF) fair value: what the stock is really worth

As of Sep 28, 2026: fair value (intrinsic value) of CARsgen Therapeutics Holdings Limited stock $0.99, price $1.62, that is 38.9% below the price, quality 54 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in China

CT CARsgen Therapeutics Holdings Limited logo Thin data Nov 10, 2026

CARsgen Therapeutics Holdings Limited

CRTHF · US
Stretched Valuation

Our calculation puts a fair price 39% below what the stock costs today.

Low debt
Revenue last quarter +22% vs. a year ago.
Quality 54/100
Mixed Growth (revenue YoY +218.7 %/yr in CNY)
Mixed vs. peers (5/9)
Fair value $0.9900 · Strongly overvalued
Loss-making · -65.3% net margin (TTM)
Negative free cash flow
Narrow moat 12/100 · thin data
Thin data
Estimate⚠ Thinly traded
Watch CARsgen Therapeutics Holdings Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$4.80 $0.7465 Fair Value $0.9900 Aug 2018 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.7465 – $4.80 · fair‑value band $0.7400 – $1.24 · the $1.62 price screens above the $0.9900 fair value. As of Nov 10, 2026.

Follow CARsgen Therapeutics Holdings in your weekly email

Every Wednesday you see whether CARsgen Therapeutics Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.

Show moreShow less

The company's products include Zevor-cel (CT053) for the treatment of relapsed/refractory multiple myeloma.

It is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial for the treatment of relapsed/refractory multiple myeloma, relapsed/refractory primary plasma cell leukemia, relapsed/refractory plasma cell leukemia, and newly diagnosed multiple myeloma.

In addition, it is developing CT0590 and CT0596, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of R/R MM, PCL; KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I. Further, the company develops KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence; KJ-C2527, which is in the pre-clinical stage to treat gastric cancer; CT1390B, which is in the pre-clinical stage to treat AML; and KJ-C2529, which is in the pre-clinical stage to treat B-cell malignancies.

Additionally, it engages in drug research and development, manufacture and import and export handling business. The company was founded in 2014 and is headquartered in Shanghai, China.

Stock analysis

CARsgen Therapeutics Holdings Limited (CRTHF) currently trades at $1.62, while our estimate is $0.9900, 39% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.7400 (bear) to $1.24 (bull), the price of $1.62 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

CARsgen Therapeutics Holdings Limited reported revenue of 126M CNY in FY2025 versus 25.8M CNY in FY2021, a compound +48.5%/yr. Reported net income was −97.9M CNY in FY2025.

Key figures

Market cap $926M Small · P/S ratio 6.76 · EPS (TTM) $−0.0200 · Net margin −77.9% · Return on equity −9.6% · Return on assets (EBIT) −26.5% (5-year average) · Operating margin −216% · Revenue (TTM) 137M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 26% below its 52-week high and 113% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −39%, CRTHF screens richer than that median.

Fair Value

Bear $0.7400 Fair Value $0.9900 Bull $1.24
Price $1.62 · Downside -38.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 54/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 97
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 58
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 80
Distance to the 52-week high, does not count
New shares 54
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+218.7%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,274.9% (2021) → −181.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CRTHF screens overvalued: fair value 39% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare CARsgen Therapeutics Holdings Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 54 · Top 25%
Fair Value upside −38.9% · Below median
Profitability
Return on assets −7.6% · Above median
Net margin (12 months) −65.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 21.5% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 7.88× · Priciest 25%
P/S (12 months) 45.18× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs CRTHF
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs CRTHF
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs CRTHF
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs CRTHF
argenx SE ARGX $971.55 $908.40 −7% vs CRTHF
CSL Limited CSL A$201.68 A$181.40 −10% vs CRTHF
Moderna, Inc MRNA $250.83 $158.70 −37% vs CRTHF
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs CRTHF
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs CRTHF
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs CRTHF

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CARsgen Therapeutics Holdings Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CARsgen Therapeutics Holdings Limited Fair Value". https://www.fairvalue-calculator.com/stock/CRTHF

Frequently asked questions

Is CARsgen Therapeutics Holdings Limited (CRTHF) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.9900 versus the last price from Sep 28, 2026 of $1.62, about 39% lower (overvalued).
What is the fair value of CRTHF?
Our estimate for CARsgen Therapeutics Holdings Limited is $0.9900 (as of Nov 10, 2026), built from audited fundamentals. Last price (from Sep 28, 2026): $1.62.
What is the quality score of CRTHF?
CARsgen Therapeutics Holdings Limited has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CARsgen Therapeutics Holdings Limited (CRTHF)?
Our calculated price target is the estimate of $0.9900 (as of Nov 10, 2026). Cautious scenario $0.7400, optimistic scenario $1.24. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CARsgen Therapeutics Holdings Limited stock forecast for 2026?
Our estimate puts fair value at $0.9900, about 39% lower versus the last price from Sep 28, 2026 of $1.62 (overvalued). Cautious scenario $0.7400, optimistic scenario $1.24. The calculation is refreshed regularly with new filings.
What is the revenue of CARsgen Therapeutics Holdings Limited (CRTHF)?
CARsgen Therapeutics Holdings Limited reported trailing-twelve-month revenue of about 137M CNY (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of CARsgen Therapeutics Holdings Limited (CRTHF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CARsgen Therapeutics Holdings Limited it is $0.9900 per share (as of Nov 10, 2026), against a price of $1.62.
Is CARsgen Therapeutics Holdings Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CRTHF trades above its calculated fair value: price $1.62, fair value $0.9900, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRTHF?
No. The price is what the market pays today ($1.62); the fair value is what the company's own numbers justify ($0.9900). For CARsgen Therapeutics Holdings Limited the two are $0.6300 per share apart. That gap is exactly why we show both numbers side by side.
How much is CARsgen Therapeutics Holdings Limited worth?
The market values CARsgen Therapeutics Holdings Limited at about $926M (market capitalisation, as of Nov 10, 2026). Per share that is $1.62; our models calculate a fair value of $0.9900 per share.
What do the bullish and bearish scenarios say about CRTHF?
Our models span a range for CARsgen Therapeutics Holdings Limited: cautious scenario $0.7400, base $0.9900, optimistic $1.24 per share (as of Nov 10, 2026, price $1.62). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CARsgen Therapeutics Holdings Limited (CRTHF)?
Balance-sheet figures for CARsgen Therapeutics Holdings Limited (as of Nov 10, 2026): return on equity −9.6%. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is CRTHF from its 52-week high?
CARsgen Therapeutics Holdings Limited trades at $1.62, about 26% below its 52-week high of $2.20 and 113% above the low of $0.7600 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.9900 is for.
Which stocks are comparable to CARsgen Therapeutics Holdings Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CARsgen Therapeutics Holdings Limited stock attractive at the current price?
The data as of Nov 10, 2026: price $1.62, calculated fair value $0.9900 (−39%), Quality Score 54/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. CARsgen Therapeutics Holdings Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CARsgen Therapeutics Holdings Limited (CRTHF)?
The latest price we hold is from Sep 28, 2026 and stands at $1.62. Our estimate is $0.9900, about 39% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CARsgen Therapeutics Holdings Limited right now?
The price sits above even our optimistic bull case ($1.24). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of CARsgen Therapeutics Holdings Limited

How large is the market capitalisation of CARsgen Therapeutics Holdings Limited (CRTHF)?
The market capitalisation of CARsgen Therapeutics Holdings Limited is $926M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CARsgen Therapeutics Holdings Limited (CRTHF)?
The price-to-sales ratio of CARsgen Therapeutics Holdings Limited is 6.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CARsgen Therapeutics Holdings Limited (CRTHF)?
Earnings per share at CARsgen Therapeutics Holdings Limited are $−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of CARsgen Therapeutics Holdings Limited (CRTHF)?
The net margin of CARsgen Therapeutics Holdings Limited is −77.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CARsgen Therapeutics Holdings Limited (CRTHF)?
The return on equity (ROE) of CARsgen Therapeutics Holdings Limited is −9.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CARsgen Therapeutics Holdings Limited (CRTHF)?
On an EBIT basis the return on assets of CARsgen Therapeutics Holdings Limited is −26.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CARsgen Therapeutics Holdings Limited (CRTHF)?
The operating margin of CARsgen Therapeutics Holdings Limited is −216% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CARsgen Therapeutics Holdings Limited (CRTHF)?
Revenue at CARsgen Therapeutics Holdings Limited is growing +21.5% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CARsgen Therapeutics Holdings Limited (CRTHF) generate?
The free cash flow of CARsgen Therapeutics Holdings Limited is −243M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch CARsgen Therapeutics Holdings Limited in the live analysis

One click puts CARsgen Therapeutics Holdings Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.